The efficacy of ICB is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in the form of processed peptide epitopes presented by major histocompatibility complex class I (MHC-I) molecules on tumour cells. Here, CD8A is linked to neoplasm.